GILD analyst estimates
Gilead (GILD) analyst ratings, the average price target and its range, and every firm's latest call.
- 16 firms rate GILD: 13 buy, 3 hold, 0 sell.
- The average price target is $168.13 from None analysts, from $126.00 to $196.00.
GILD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 18, 2026 | TD Cowen | TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD) | $175.00 |
| Nov 12, 2026 | Argus Research | Gilead Sciences (GILD) PT Raised to $190 at Argus | $190.00 |
| Nov 4, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Gilead Sciences (GILD) | $196.00 |
| Nov 2, 2026 | Bernstein | Gilead Sciences (GILD) PT Raised to $175 at Bernstein SocGen Group | $175.00 |
| Oct 30, 2026 | BMO Capital | Gilead Sciences (GILD) PT Raised to $184 at BMO Capital | $184.00 |
| Oct 30, 2026 | Needham | Gilead Sciences (GILD) PT Raised to $175 at TD Cowen | $175.00 |
| Oct 30, 2026 | UBS | Gilead Sciences (GILD) PT Raised to $195 at UBS on Revenue Beat, Raised Guidance | $195.00 |
| Oct 23, 2026 | Jefferies | Gilead Sciences (GILD) PT Raised to $185 at Jefferies | $185.00 |
| Oct 20, 2026 | Bank of America Securities | Gilead Sciences (GILD) PT Raised to $172 at BofA Securities | $172.00 |
| Oct 12, 2026 | Raymond James | Gilead Sciences (GILD) PT Raised to $164 at BofA Securities | $164.00 |
| Oct 8, 2026 | RBC Capital | Gilead price target raised to $126 from $123 at RBC Capital | $126.00 |
| Oct 7, 2026 | Truist Financial | Gilead price target raised to $158 from $150 at Truist | $158.00 |
| Sep 10, 2026 | HSBC | Gilead price target raised to $175 from $155 at HSBC | $175.00 |
| Aug 5, 2026 | RBC Capital | Gilead price target raised to $123 from $120 at RBC Capital | $123.00 |
| Aug 5, 2026 | Truist Financial | Gilead price target lowered to $150 from $156 at Truist | $150.00 |